Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-BeST: Betahistine and Selegiline PK Study
NCT05938517Phase 1Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selegiline in Ménière's disease (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Mean Area Under the Curve of Betahistine. Started Jun 2021; status: completed.
02
Drugs
selegiline
03
Conditions
Ménière's disease
Beyond the preview
Go deeper on NCT05938517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938517.